Patrick Forde, Professor at The Johns Hopkins University, shared a post on X:
“Big news in small cell lung cancer, a disease which historically has had a very poor prognosis. The T cell engager, tarlatamab improves survival vs. 2nd line chemo. Hope is that durable responses will be seen and early phase data were encouraging.”